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1. Introduction 
An outstanding biochemical characteristic of neoplastic tissues is that despite ample oxygen 
supply, glycolysis is the dominant pathway for adenosine 5'-triphosphate (ATP) production, 
a phenomenon termed “the Warburg effect” (Warburg et al., 1927; Warburg, 1956). This 
aerobic glycolysis seems unexpected as one would imagine that cancer cells should have, 
given sufficient oxygen, adapted to utilize the complete oxidative phosphorylation to 
maximize ATP production. In addition, for producing same level of ATP, glycolysis would 
consume >15-fold more glucose, resulting in an addiction for glucose during active tumor 
growth. There must be a biological logic for cancer cells to prefer utilization of glycolysis for 
ATP production: they obtain and/or sustain growth advantage at the cost of an “addiction” 
to glycolysis. Mechanistically, there have been many hypotheses proposed to explain this 
phenomenon and two are more prominent: one is that by consuming excessive glucose, 
cancer cells may change the tumor’s microenvironment to gain growth advantage over 
normal cells; the second is that, to sustain a dominant glycolysis process, cancer cells alter 
the expression or functions of glucose metabolic enzymes, which may have resulted in 
additional changes that promote cancer development (Vander Heiden et al., 2009). A 
growing body of evidence has supported both hypotheses and will be reviewed here. 
2. Altered glycolytic enzymes in cancer cells 
In cancer cells, the activities or expression levels of many enzymes participating in glucose 
metabolism are altered, those involved in glycolysis in particular. The glycolysis commonly 
refers to the reactions that covert glucose into pyruvate or lactate (Figure 1). Usually, one or 
more isoforms of glycolytic enzymes have altered expression patterns or activities in cancer 
cells, which was previously reviewed (Herling et al., 2011; Porporato et al., 2011). 
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Fig. 1. Glycolysis in cancer cells  
 GLUT1, an isoform of glucose transporters (GLUTs) is overexpressed in many types of 
human malignancies, whereas the insulin-sensitive GLUT4 is downregulated in cancer 
cells. The imbalanced expression of GLUT1 versus GLUT4 in cancer cells may have 
contributed to the insulin-independent glucose uptake in cancer cells. In addition, 
GLUT3 was also reported to be overexpressed in cancer cells (Smith, 1999; Medina and 
Owen, 2002; Noguchi et al., 1998). 
 HK-2, an isoform of hexokinase that is one of the three rate limiting glycolytic enzymes, 
is overexpressed in cancer cells and was shown to contribute to the Warburg effect. The 
high glycolytic rate characteristic of hypoxic solid tumors is attributed to the 
overexpression of HK-2 (Mathupala et al., 2009; Wolf et al.). 
 The expression level of the glucose 6-phosphate isomerase (GPI) has also been 
reported to be elevated in its mRNA level in different human cancer cell lines 
(Funasaka et al., 2005).  
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 The alteration of phosphofructokinase-1 (PFK-1) in cancer cells is not at expression 
level, but at the level of the enzyme activity. PFK in cancer cells is less sensitive to the 
inhibition by its allosteric regulators such as citrate and ATP (Meldolesi et al., 1976). 
Additionally, the expression of all four genes of the Phosphofructokinase-2 (PFK-
2/FBPase/PFKFB) family is inducible by hypoxia, among which the gene encoding 
PFKFB3 is highly expressed in several types of human neoplasm (Minchenko et al., 
2005; Atsumi et al., 2002; Kessler et al., 2008).  
 The expression of aldolase isoenzymes is downregulated in some cancer types such as 
hepatocellular carcinoma (Song et al., 2004) and upregulated in some other tumor types 
such as pancreatic ductal adenocarcinoma (Cui et al., 2009).  
 Triosephosphate isomerase (TPI) was detected in the plasma of cancer patients (Robert 
et al., 1961) and autoantibodies against TPI was also detected in sera from breast cancer 
patients (Tamesa et al., 2009).  
 Phosphoglycerate kinase-1 (PGK-1) is overexpressed in majority of the pancreatic 
ductal adenocarcinomas and can also be detected in sera of patients with these tumors 
(Hwang et al., 2006).  
 Phosphoglycerate mutase (PGM/PGAM) M type subunit (PGM-M) is overexpressed 
in many cancers including lung, colon, liver and breast (Durany et al., 2000; Durany 
et al., 1997).  
 The expression of Enolase 1 (ENOA) is upregulated at the transcriptional and ⁄ or 
translational level in multiple types of tumor including brain, breast, cervix, colon, eye, 
gastric, head and neck, kidney, leukemia, liver, lung, muscle, ovary, pancreas, prostate, 
skin and testis(Capello et al.). It is also differentially regulated at the post-translational 
level in cancer cells as compared with normal cells. ENOA in tumor cells is subjected to 
more acetylation, methylation and phoshorylation than in normal tissues (Capello et al.). 
Specific acetylated residues of ENOA were found in cervix, pancreatic, and colon cancers. 
Five aspartate and five glutamate residues were found to be specifically methylated in 
pancreatic cancer. Several serine and threonine residues were found to be specifically 
phosphorylated in leukemia, cervix, and lung cancers. Although ENOA is 
phosphorylated at Serine 419 in both normal and malignant pancreatic tissues, this 
phosphorylated form of ENOA is overexpressed in pancreatic cancer(Zhou et al., 2010). 
 Pyruvate kinase has two isoforms, M and L, which have tissue-specific expression. 
Normal proliferating cells including embryonic cells and adult stem cells selectively 
express the M2 isoform (PKM2) (Reinacher and Eigenbrodt, 1981; Yamada and 
Noguchi, 1999). During tissue differentiation in development, embryonic PKM2 is 
replaced by tissue-specific isoforms. However, the tissue-specific expression pattern of 
PK is disrupted during tumorigenesis (Hacker et al., 1998). PKM2 is re-expressed and 
becomes the only predominant isoform in cancer cells (Mazurek et al., 2005).  
 The lactate dehydrogenase (LDH) family of tetrameric enzymes catalyzes the pyruvate 
reduction into lactate. LDHs are formed by four subunits of two different isozymes of 
either LDH-H or LDH-M. LDH-H is encoded by the LDH-B gene and is ubiquitously 
expressed, and LDH-M is encoded by LDH-A. LDH-M has a higher Km for pyruvate 
and a higher Vmax for pyruvate reduction than LDH-H (Markert et al., 1975). 
Consequently, LDHs predominantly comprising of the LDH-M subunits drive the 
reduction of pyruvate to lactate; LDHs predominantly comprising of the LDH-H 
subunits drive the oxidation of lactate to pyruvate. Many types of tumor cells manifest 
a high expression of the LDH-A gene. Elevated expression of LDH5, which comprises of 
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four LDH-M subunits, is an unfavorable prognostic factor for many human 
malignancies (Koukourakis et al., 2003; Koukourakis et al., 2005; Koukourakis et al., 
2009). In addition, the glycolysis process in cancer cells is reportedly to be associated 
with hypermethylation of the LDH-B gene promoter, which is linked to gene silencing 
(Leiblich et al., 2006; Thangaraju et al., 2009).  
 Plasma membrane lactate transport (LACT) is facilitated by the family of proton-linked 
moncarboxylate transporters (MCTs) or by SMCT1, a sodium coupled lactate 
transporter. The MCT4 isoform is upregulated in many cancer types. The expression of 
MCT2, an isoform mainly implicated in lactate import, is decreased in tumor cell lines. 
SMCT1, also implicated in lactate import, is downregulated in a number of cancer types 
including colon, thyroid, and stomach(Herling et al., 2011; Porporato et al., 2011).  
3. Glucose metabolic pathways switched by oncogenes and tumor 
suppressors 
It has been long proposed that the altered expression or enzyme activities of glycolytic 
enzymes are regulated by oncogenes and tumor suppressor genes. 
 The expression of GLUT1 has been demonstrated to be controlled by the hypoxia-
inducible transcription factor HIF-1, c-Myc, and Akt (Chen et al., 2001; Osthus et al., 
2000; Rathmell et al., 2003).  
 The gene encoding HK-2, but not HK-1, is known to be a transcriptional target of HIF-
1(Rempel et al., 1996). It was later shown that HIF-1 cooperates with c-Myc to 
transactivate HK-2 under hypoxia (Kim et al., 2007). The phosphorylated form of HK-2 
interacts with the voltage-dependent anion channel (VDAC) at the outer mitochondrial 
membrane (Bustamante and Pedersen, 1977; Nakashima et al., 1986; Gottlob et al., 
2001). The interaction of HK-2 with VDAC interferes with the binding of the pro-
apoptotic protein Bax to VDAC thus preventing the formation of the channel through 
which cytochrome c can escape from mitochondria to trigger apoptosis (Pastorino et al., 
2002). Therefore, overexpression of HK-2 in cancer cells leads to a switch from HK-1 to 
HK-2 and offers a metabolic advantage by protecting cancer cells against 
apoptosis(Porporato et al., 2011). 
 Overexpression of GPI can be induced by HIF-1 and VEGF(Funasaka et al., 2005). 
 The expression of PFK-2 genes in tumor cells is shown to be regulated by Ras and src 
(Yalcin et al., 2009) and that of PFKFB3 is demonstrated to be induced by HIF-1, c-
myc, ras, src, and loss of function of p53 (Minchenko et al., 2002). Among the four 
PFK-2 genes, PFKFB3 is the most significantly induced in response to hypoxia. 
Hypoxia-induced PFK-2 activity of human PFKFB3 is further enhanced through 
phosphorylation of the serine 462 residue (Marsin et al., 2002). This phosphorylation 
process may involve AMP-activated protein kinase (AMPK) and Akt(Shaw and 
Cantley, 2006; Yun et al., 2005).  
 Although no evidence has suggested that the expression level of Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) is altered in cancer cells, its expression has been 
demonstrated to be highly dependent on the proliferative state of the cells and can by 
regulated by HIF-1, p53, and c-jun(Colell et al., 2009; Colell et al., 2007).  
 The gene encoding ENOA is a target of, and its expression is upregulated by, c-Myc 
(Sedoris et al. 2010). Notably, a growing body of evidence has suggested that ENOA 
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is a tumor-associated antigen(Capello et al., 2011). In patients of many different 
cancer types, including pancreatic, leukemia, melanoma, head and neck, breast and 
lung, anti-ENOA autoantibodies have been detected(Capello et al., 2011). In 
pancreatic cancer patients, the anti-ENOA autoantibodies are directed against 
phosphorylated Serine 419(Tomaino et al., 2011). One study has shown that, in 
pancreatic cancer, ENOA elicits a CD4+ and CD8+ T cell response both in vitro and in 
vivo (Cappello et al., 2009). In pancreatic cancer patients, production of anti-ENOA 
IgG is correlated with the ability of T cells to be activated in response to 
ENOA(Cappello et al., 2009). In patients with oral squamous cell carcinoma, an HLA-
DR8-restricted peptide (amino acid residues 321–336) of human ENOA recognized by 
CD4+ T cell has been identified (Kondo et al., 2002). 
 As described above, PKM2 is a predominant isoform of PKM in cancer cells. PKM2 is 
less active than other PKs but is however the only PK subject to regulation by the 
allosteric activator fructose-1,6-bi-phosphate (FBP) and possessing the capability to bind 
phosphotyrosine proteins (Christofk et al., 2008). Binding of phosphotyrosine peptides 
to PKM2 leads to dissociation of FBP hence lowering the PKM2 enzyme activity, which 
may provide a link between cell growth signals and the Warburg effect given that many 
growth signals and oncogenic pathways involve tyrosine kinases. The unique feature of 
the PKM2 isoform provides a mechanism by which oncogenes regulate glycolysis and 
the Warburg effect, and offers an advantage in metabolic plasticity by equipping cancer 
cells with an exquisitely regulated switch between promoting ATP production and cell 
proliferation; and lowering the PKM2 activity upon growth signaling was proposed to 
allow efficient biomass building (anabolic) pathways branched from glycolysis 
(Christofk et al., 2008). It was suggested that PKM2 is regulated by HIF-1 at the 
transcriptional level (Discher et al., 1998). Recently, it was demonstrated that, after 
nuclear translocation, PKM2 cooperates with HIF-1 to transactivate genes, the products 
of which are involved in promoting the glycolysis and tumor angiogenesis (Luo et al., 
2011). Despite these advancements, the regulatory mechanism of PKM2 in cancer cells 
is not fully understood.  
 The expression of PGM/PGAM was found to be downregulated by p53 (Kondoh et al., 
2005). Thus, loss of p53 function is anticipated to induce the expression of 
PGM/PGAM. Phosphoenolpyruvatue, the substrate for PK in cells, transfers the 
phosphate to the histidine residue located in the catalytic center of the human PGAM1; 
however, this reaction occurs only in those PKM2-expressing cells but is independent of 
the PKM2 enzyme activity. Thus, histidine phosphorylation of PGAM1 may provide an 
alternate glycolytic step in proliferating cancer cells where low PK activity accompanies 
the expression of PKM2 (Vander Heiden et al., 2010b).  
 LDH-A is a target gene of c-Myc and HIF-1 (Dang et al., 2009). Loss of LDH-A functions 
results in diminished cellular transformation, anchorage independent tumor growth 
under hypoxic conditions, or xenograft tumor growth (Shim et al., 1997).  
Therefore, activation of oncogenes and loss of tumor suppressors are believed to underlie 
the metabolic switch in cancer cells. Many cancer associated gene products are involved, 
including c-Myc, NF-kB, Akt, and multiple types of tyrosine kinase including epidermal 
growth factors (EGFs) and insulin-like growth factor 1 (IGF-1) receptor (Levine and Puzio-
Kuter, 2010). Several pathways have been shown to be important for the regulation of 
glucose metabolism including the PI3K-AKT-mTOR and c-Myc pathways and both have 
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HIF-1 as their downstream effector. Consistently, among the HIF-1 regulated genes, most 
are those encoding glycolytic enzymes (Semenza, 2003). The loss of PTEN and concurrent 
increase of Akt and mTOR lead to the HIF-1 activation and the Warburg effect (Arsham et 
al., 2002; Zundel et al., 2000).  
Another oncogene, K-Ras, can alter glucose metabolism so as to provide tumor cells with a 
selective advantage. In cells with mutated K-Ras, GLUT1 is upregulated, leading to an 
augmented glucose uptake, glycolysis and lactate production. Interestingly, in these cells 
mitochondrial functions and oxidative phosphorylation are not compromised, which allows 
increased survival rate of the K-Ras mutant cells during glucose deprivation (Annibaldi and 
Widmann, 2010). 
Loss of p53 functions also leads to the Warburg effect. As described above, p53 represses 
transcription of the genes encoding GLUT1 and 4, and induces transcription of the TIGAR 
gene, which in turn lowers the intracellular level of PFK/FBPase (Bensaad et al., 2006). In 
addition, p53 inhibits the PI3K-Akt-mTOR pathways. This appears to be mediated by the 
transcriptional targets of p53 including PTEN, IGF-binding protein 3, tuberous sclerosis 
protein TSC-2, and the beta subunit of AMPK (Feng et al., 2007). Conceivably, loss of p53 
functions and subsequent loss of expression of these target genes lead to a high HIF level 
and establishment of the Warburg effect. 
4. Tumor “friendly” microenvironment attributed to altered glucose 
metabolism 
One would ask: what is the advantage for cancer cells to use energy-inefficient glycolysis 
under adequate oxygen supply. A potential advantage, as a result of Warburg effect, is high 
production of lactic acid due to enhanced glycolysis. Positive correlation between lactate 
serum levels and tumor burden in cancer patients has been well documented, implicating a 
role of acidic microenvironment in promoting tumor growth and development (McCarty 
and Whitaker, 2011).  
First, accumulated evidence has suggested that acidic environment amplifies the capacity of 
invasion and metastasis of cancer cells. For instance, acid pretreatment of tumor cells 
enhance their ability to form metastases in tumor-transplanted mice (Rofstad et al., 2006). 
Consistently, it has been shown that increasing tumor pH via bicarbonate therapy 
significantly reduces the number and the size of metastases in a mouse model of breast 
cancer (Robey et al., 2009).  
Second, the extracellular pH of solid tumors is significantly more acidic than that of normal 
tissues, thus impairing the uptake of weakly basic chemotherapeutic drugs (Raghunand et 
al., 1999). Several anticancer drugs such as doxorubicin, mitoxantrone and vincristine are 
weak bases that are protonated in slightly acid tumor microenvironments. The protonated 
forms of the drugs cannot easily diffuse across the plasma membrane and therefore their 
cellular uptake is suppressed. It has been demonstrated that the addition of sodium 
bicarbonate in the drinking water enhanced the anti-tumor effect of doxorubicin on 
xenotransplanted tumors presumably by enhancing the intracellular drug delivery through 
raising the pH of the extracellular milieu in mice (Raghunand et al., 1999). The reverse 
situation was also demonstrated in another study showing that glucose administration to 
mice led to a lower efficacy of doxorubicin on tumors presumably due to a decrease in the 
extracellular pH (Gerweck et al., 2006).  
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Third, acidic microenvironment inhibits anti-tumor immune response. For instance, lactic 
acid suppressed the proliferation and cytokine production of human cytotoxic T 
lymphocytes (CTLs) up to 95% and led to a 50% decrease in cytotoxic activity (Fischer et al., 
2007). Activated lymphocytes themselves use glycolysis, which relies on the efficient 
secretion of lactic acid. Export of lactic acid from lymphocytes depends on a gradient 
between intracellular and extracellular lactic acid concentration. High extracelullar acidity 
would diminish this gradient and block the secretion of lactic acid from lymphocytes. The 
accumulation of intracellular lactic acid eventually disturbs the glycolysis process hence 
affecting the activity of lymphocytes. Acidification similarly inhibits the activity of other 
immune cells such as dendritic cells.  
5. Coupled biological and metabolic processes and the logic of a mammalian 
metabolic cycle 
Glycolytic enzymes have multiple cellular functions. For instance, GAPDH has been 
implicated in numerous non-glycolytic functions (Colell et al., 2007; McKnight, 2003). In 
2003, we published a paper that describes the isolation and characterization of OCA-S, 
which is a transcription cofactor complex that directly stimulates the transcription of the 
histone H2B gene in an S-phase-specific manner (Zheng et al., 2003). Surprisingly, a key 
component of the OCA-S complex represents a nuclear form of GAPDH, which regulates 
H2B transcription in a redox dependent manner. LDH was later shown to be an essential 
OCA-S component as well and can exercise the enzyme activity to reverse in vitro inhibition 
of H2B transcription by converting NADH to NAD+ in the presence of substrate pyruvate 
(Dai et al., 2008). Conceivably, the participation of these glycolytic enzymes in such a cell 
cycle event would subject cell cycle regulation to altered glucose metabolism in cancer cells, 
providing yet another mechanistic explanation of cancer growth and development. The 
“moonlighting” participation of the glycolytic enzymes in a cellular process would in theory 
impose a dynamic modulation of the redox status in the cellular compartment where this 
process is executed and subsequently affect the functions of other redox-sensitive proteins in 
the same intracellular compartment. Thus, in addition to histone expression, our study has 
suggested that other cellular processes including cell cycle regulation, DNA replication and 
damage repair are potentially all coupled through the redox signals (Yu et al., 2009). The 
coupling of these cellular processes is apparently crucial for the maintenance of chromatin 
integrity during cell cycle, and thus altered glucose metabolism in cancer cells potentially 
would disrupt the coupling of these processes and make cancer genomes more error-prone.  
It is well delineated that in yeast, quite a few biological and metabolic processes are known 
to be compartmentalized in time, termed the yeast metabolic cycle (YMC) that is in sync 
with the cell cycle progression (Tu et al., 2005). The YMC has oxidative, reductive/building 
and reductive/charging phases, and the S-phase of yeast cell is synchronized with the most 
reductive stage of YMC. We subsequently found that the oxidative and reductive phases in 
mammalian cells are also synchronized with the cell cycle, and our study demonstrated that 
the free NAD+/NADH ratio fluctuated in a defined manner during cell cycle(Yu et al., 
2009). At G1 phase, the intracellular NAD+/NADH ratio is high, suggesting that G1 cells 
maintain an oxidative status. Upon entering S phase, the ratio becomes lower, 
corresponding to a reductive status. When the cells exit S phase and enter G2 phase, the 
NAD+/NADH ratio becomes higher again. This oxidative status appears to be maintained 
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until cells enter the next S phase. This phenomenon has been dubbed mammalian metabolic 
cycle (MMC) for its similarity with YMC. The fluctuating NAD+/NADH ratios in a 
mammalian cell cycle must reflect overall oscillatory cellular metabolism; whether and how 
glucose metabolism is synchronized with the cell cycle remains to be explored. Nonetheless, 
this synchronization must have been very precisely regulated. Conceivably, if glucose 
metabolism is altered, the cell cycle must be coordinately modulated, and vice versa. 
Therefore, cancer cells may have acquired the growth and proliferative advantage over 
normal cells through alteration in glucose metabolism.  
6. Targeting glycolysis for cancer treatment 
The aberrant metabolic pathways underlying the Warburg effect are being considered as 
novel targets for cancer therapy. Several strategies have been employed to target glucose 
metabolic pathways for cancer treatment.  
First, inhibitors of glycolytic enzymes or glycolytic pathways are being searched to identify 
therapeutic agents that can inhibit cancer growth and development.  
A number of small molecules have been reported to target glycolysis although none to date 
has been shown to have specific molecular targets. For example, 3-bromopyruvate, a highly 
active alkylating agent, was reported to target HK-2 and/or GAPDH (Dang et al., 2009). 2-
deoxyglucose (2-DG) can be phosphorylated by HK-2, which in turn inhibits HK-2 (Ralser et 
al., 2008). It is also shown to be a GLUT inhibitor.  
Many efforts have been made to identify specific inhibitors. Lonidamine has been described as 
a specific inhibitor of mitochondria-bound HK (Floridi et al., 1981) and has been tested in 
multiple clinical trials including a phase II study in combination with diazepam for the 
treatment of glioblastoma patients (Porporato et al., 2011). Unfortunately, none of these clinical 
trials have successfully shown its therapeutic benefit in terms of time-to-progression and 
overall survival (Oudard et al., 2003); one study showed its severe hepatic adverse effects.  
Drugs that target more specific metabolic control points of glycolysis in cancer cells, such as 
PKM2 or LDH-A, warrant investigation as potential cancer therapies. gossypol/AT-101, a 
natural product and a non-specific LDH inhibitor that has more preferential inhibitory activity 
on malarial and spermoctye LDHs, has already been tested in human clinical trials for its anti-
cancer effect(Porporato et al., 2011). A selective competitive inhibitor of LDH5, 3-dihydroxy-6-
methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxylicacid (FX11), has been identified 
through screening a library of compounds derived from gossypol (Yu et al., 2001). FX11 has 
been shown to suppress in vivo xenograft tumor growth of human B lymphoid tumor and 
pancreatic cancer cells (Le et al. 2010), providing a strong rationale for clinical development of 
therapeutic agents targeting LDH-A. Recently, N-Hydroxy-2-carboxy-substituted indole 
compounds have been identified as LDH5-specific inhibitors (Granchi et al., 2011). 
Several clinical trials with the PKM2 inhibitor TLN-232/CAP-232, a seven amino-acid 
peptide, have been initiated. Encouraging preliminary results demonstrated that it is safe, 
well tolerated, and may offer disease control (Porporato et al., 2011). New small molecule 
inhibitors of PKM2 were also screened. Among them, the most potent one resulted in 
decreased glycolysis and increased cell death in respond to loss of growth factor signaling, 
supporting the feasibility and viability of targeting glucose metabolism as a novel strategy 
to treating human cancers (Vander Heiden et al., 2010a).  
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Conceivably, ENOA, as a tumor-associated antigen with an ability of eliciting both B cell 
and T cell immune response (Capello et al., 2011), is an ideal target of cancer vaccine and 
immunotherapy. Comparing to small molecule inhibitors, immunotherapy offers superior 
target specificity and may be used as an alternative approach to target other glycolysis 
enzymes.  
Second, inhibition of glycolytic enzyme or glycolysis pathways serves as a strategy to 
enhance the sensitivity of tumor cells to conventional cytotoxic chemotherapy agents.  
Inhibition of LDH-A has been shown to re-sensitize Taxol-resistant cancer cells to Taxol 
(Zhou et al.). 2-DG is another example. The safety of using it as an anti-cancer agent has 
been questioned notably because of brain toxicity (Tennant et al., 2010). However, it has a 
proven efficacy in sensitizing human osteosarcoma and non-small cell lung cancers to 
adriamycin and paclitaxel (Maschek et al., 2004). Recently, a Phase I clinical study for 
prostate cancer has defined a maximum tolerance dose of 45mg/kg for Phase II trials (Stein 
et al., 2010). It will be interesting to test whether 2-DG can enhance the efficacy of 
chemotherapy agents even if it cannot offer anti-cancer activity by itself at this dose level.  
As aforementioned, chemosensitivity is enhanced by counteracting the acidification of 
tumor’s microenvironment. Inhibitors of glycolytic enzymes may impose an alkalizing effect 
in tumor’s microenvironment particularly at the tumor tissue level and thus may have a 
more specific and powerful role in enhancing the sensitivity of tumor cells to basic 
chemotherapy drugs. Major targets for counteracting the acidification of tumor’s 
microenvironment include carbonic anhydrasesis (CA)-9 and -12, sodium–proton exchanger 
1 (NHE1), sodium bicarbonate cotransporter (NBC), vacuolar ATPase (V-ATPase), sodium–
potassium (NaK) ATPase, and MCT4 (Porporato et al., 2011). Indisulam is a leading 
compound for CA9 inhibition. It is a sulfonamide derivative and shown to inhibit CA9 at 
nanomolar concentrations (Abbate et al., 2004; Supuran, 2008; Owa et al., 2002). It has been 
tested in multiple clinical trials for the treatment of melanoma, lung, pancreatic and 
metastatic breast cancers and has not been found in the completed clinical trials to have 
antitumor efficacy as a single agent (Talbot et al., 2007). Girentuximab, a specific antibody 
targeting CA9, is now being tested in Phase III clinical trials for the treatment of clear-cell 
renal cell carcinoma (Reichert, 2011). Several inhibitors of membrane-bound V-ATPase have 
been reported to have antitumor activity in preclinical studies (Perez-Sayans et al., 2009). 
Other enzymes involved in the cellular export of protons are also studied as targets of anti-
cancer therapeutic development. However, future studies should emphasize on combining 
anti-acidification therapies with cytotoxic chemotherapy or immunotherapy to achieve the 
effective anti-cancer treatment.  
Third, combination of inhibitors of glucose metabolic enzymes with inhibitors of oncogenic 
pathways may result in synergistic anti-tumor effects.  
Inhibitors of oncogenic pathways have been extensively tested for cancer therapy, with only 
moderate success in a few types of human cancers. Among them, inhibitors of the Ras 
pathway are essentially not effective. As K-ras mutated cancer cells have an enhanced 
survival when glucose is deprived, a combinatorial treatment with both glycolysis inhibitors 
and Ras pathway inhibitors may target Ras-mutated cancer cells more effectively and more 
specifically. Supporting this hypothesis, the hexokinase inhibitor 3-bromopyruvate was 
demonstrated to be highly toxic specifically to cancer cells with K-ras mutation, but not to 
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cancer cells with wild-type K-ras (Yun et al., 2009). BAY87-2243, which is a small molecule 
inhibitor of HIF-1 activity and of HIF-1α stability, and EZN-2968, which is an antisense 
oligonucleotide targeting HIF-1α, had been tested in clinical trials (Greenberger et al., 2008). 
Metformin is an AMPK-activating drug and is currently used for type-2 diabetes treatment. 
Epidemiological studies have shown reduced incidence of cancer in diabetic patients treated 
with metformin (Evans et al., 2005; Jalving et al., 2010; Libby et al., 2009). It is highly 
intriguing to test whether this clinically safe and known glucose metabolism modulating 
drug can enhance anti-cancer activity of cytotoxic chemotherapy and/or further lower the 
cancer recurrence following adjuvant chemotherapy. Similarly, other combination 
treatments with inhibitors of both glucose metabolisms and oncogenic pathways such as 
Akt, mTOR, etc. also warrant investigation.  
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associated areas. The book is written by international scientists with expertise in protein biochemistry,
enzymology, molecular biology and genetics many of which are active in biochemical and biomedical research.
We hope that the book will enhance the knowledge of scientists in the complexities of some biochemical
approaches; it will stimulate both professionals and students to dedicate part of their future research in
understanding relevant mechanisms and applications of biochemistry.
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